GlassScriptPhysician profile
Ronald Intini
NPI 1841397858
$8,966.09
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,234 · 2020: $1,962 · 2021: $3,481 · 2022: $1,290.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,900.97 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $931.32 | 2019-2022 | |
| Amgen INC. | $910.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $865.35 | 2019-2022 | |
| Amarin Pharma, INC. | $720.15 | 2019-2022 | |
| Abbvie INC. | $435.93 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $390.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.06 | 2019-2022 | |
| Lilly USA, LLC | $375.68 | 2019-2022 | |
| Esperion Therapeutics, INC. | $343.28 | 2020-2021 | |
| Pfizer INC. | $294.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $242.74 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $154.34 | 2020-2022 | |
| Allergan, INC. | $131.56 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $98.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $97.25 | 2019-2021 | |
| Astellas Pharma US INC | $56.06 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.31 | 2020-2021 | |
| Abbott Laboratories | $47.69 | 2021-2022 | |
| Mylan Specialty L.P. | $46.42 | 2021 | |
| Jazz Pharmaceuticals INC. | $44.97 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $44.45 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $40.16 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $40.01 | 2019-2021 | |
| Genentech USA, INC. | $27.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.14 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.73 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.66 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.86 | 2021 | |
| Redhill Biopharma INC. | $13.19 | 2020 | |
| Eisai INC. | $11.86 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Intini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.